Zinc-oxyde Plus

Menthol, Zinc Oxide


First Aid Research Corp.
Human Otc Drug
NDC 75983-006
Zinc-oxyde Plus also known as Menthol, Zinc Oxide is a human otc drug labeled by 'First Aid Research Corp.'. National Drug Code (NDC) number for Zinc-oxyde Plus is 75983-006. This drug is available in dosage form of Ointment. The names of the active, medicinal ingredients in Zinc-oxyde Plus drug includes Menthol - 4.4 mg/g Zinc Oxide - 206 mg/g . The currest status of Zinc-oxyde Plus drug is Active.

Drug Information:

Drug NDC: 75983-006
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Zinc-oxyde Plus
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Menthol, Zinc Oxide
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: First Aid Research Corp.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Ointment
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:MENTHOL - 4.4 mg/g
ZINC OXIDE - 206 mg/g
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 06 Nov, 2019
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 22 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part346
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:First Aid Research Corp.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:2123045
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:L7T10EIP3A
SOI2LOH54Z
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Copper Absorption Inhibitor [EPC]
Decreased Copper Ion Absorption [PE]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
75983-006-571 TUBE in 1 CARTON (75983-006-57) / 57 g in 1 TUBE06 Nov, 2019N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose external analgesic / anti-itch skin protectant / anorectal astringent

Product Elements:

Zinc-oxyde plus menthol, zinc oxide butylated hydroxytoluene cetyl esters wax glycerin glyceryl monostearate lanolin polyoxyl 40 hydrogenated castor oil phenol sodium bicarbonate thymol petrolatum menthol menthol zinc oxide zinc cation

Indications and Usage:

Uses a moisture barrier that prevents and helps heal skin irritation from: • urine • diarrhea • perspiration • fistula damage • feeding tube site leakage • wound drainage (peri-wound skin) • minor burns • cuts • scrapes • itching

Warnings:

Warnings for external use only • not for deep or puncture wounds • avoid contact with eyes stop use and ask a doctor • if condition worsens or does not improve within 7 days. keep out of reach of children. in case of accidental ingestion contact a physician or poison control center immediately.

Dosage and Administration:

Directions cleanse skin gently with mild skin cleanser pat dry or allow to air dry apply a thin layer of ointment to reddened or irritated skin 2-4 times daily, or after each incontinent episode or diaper change to promote comfort and long lasting protection.

Stop Use:

Stop use and ask a doctor • if condition worsens or does not improve within 7 days.

Package Label Principal Display Panel:

Label

Further Questions:

Questions? call 516-783-0274


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.